Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7RTS9
UPID:
DYM_HUMAN
Alternative names:
Dyggve-Melchior-Clausen syndrome protein
Alternative UPACC:
Q7RTS9; A8K5I8; B2RCF9; B4DKI7; Q3ZTS8; Q6P2P5; Q8N2M0; Q9BVE9; Q9NPU7
Background:
Dymeclin, also known as the Dyggve-Melchior-Clausen syndrome protein, plays a crucial role in the correct organization of the Golgi apparatus and is pivotal in bone development. This protein's involvement in such fundamental cellular processes underscores its importance in human physiology.
Therapeutic significance:
Dymeclin is directly associated with Dyggve-Melchior-Clausen syndrome and Smith-McCort dysplasia 1, both rare genetic disorders affecting bone growth and development. Understanding the role of Dymeclin could open doors to potential therapeutic strategies for these conditions, highlighting the importance of targeted research in uncovering novel treatments.